Tf–idf

$15.8 Billion Worldwide Wireless POS Terminals Industry to 2027 - Key Players Include Ingenico, Verifone, First Data and PAX Global Technology

Retrieved on: 
Friday, January 13, 2023
First Data, Squirrel Systems, ShopKeep, COVID-19, Diebold Nixdorf, Point, Wireless, Tablet, PIN, Museum, Revel Systems, Software, Pharmacy, POS, Metro, Tf–idf, TouchBistro Inc., NCR Corporation, Restaurant, Cryptocurrency, Payment card, Internet service provider, Ingenico, Growth, Verifone, Wends

The global wireless POS terminals market size reached US$ 8.3 Billion in 2021.

Key Points: 
  • The global wireless POS terminals market size reached US$ 8.3 Billion in 2021.
  • What are the key driving factors and challenges in the global wireless POS terminals market?
  • What is the structure of the global wireless POS terminals market and who are the key players?
  • What is the degree of competition in the global wireless POS terminals market?

Global Wireless POS Terminals Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Payments, Apps, Applications, Technology, Mobile, Wireless, Software, Hardware, Pharmacy, POS, Point, Museum, Metro, Tablet, Tf–idf, MPOS, PIN, Restaurant, Software, COVID-19, Cryptocurrency, Payment card

A wireless POS terminal (Point of Sale) is a digital device employed to process card payments in banks, retail stores, museums, metro stations, pharmacies and restaurants.

Key Points: 
  • A wireless POS terminal (Point of Sale) is a digital device employed to process card payments in banks, retail stores, museums, metro stations, pharmacies and restaurants.
  • Introduction of Personal Identification Number (PIN) and chip-embedded payment cards have minimized security-related concerns, thereby creating a positive outlook for the global wireless POS terminals market.
  • The publisher provides an analysis of the key trends in each sub-segment of the global wireless POS terminals market report, along with forecasts at the global and regional level from 2022-2027.
  • Based on the component, the market has been segmented into hardware, and POS software and services.

EQS-News: Mobile TeleSystems PJSC: NOTICE OF MEETING

Retrieved on: 
Sunday, November 27, 2022
Euroclear, DTC, Condition, Trust deed, Trustee Sales Guarantee, Loan agreement, Competence, MTS, Schedule 4, Meeting, Proxy, Protected trust deed, Extraordinary resolution, Tf–idf, Amendment, Agency agreement, Person, Donald Duck filmography, Proposal, Trust, Failure, News, Mechanics, KYC, Acquisition, Principal, Direct Payments, Trustee, Information, RS, Loan, Security (finance), Real estate, Cryptocurrency, Property management, Financial adviser, Memorandum, Note, Issuer, Limited

MTS PJSC (the "Company") hereby requests that the holders of U.S.$500,000,000 5 per cent.

Key Points: 
  • MTS PJSC (the "Company") hereby requests that the holders of U.S.$500,000,000 5 per cent.
  • Terms not otherwise defined in this Extraordinary Resolution shall have the meaning ascribed thereto in the Consent Solicitation Memorandum dated 21 November 2022.
  • 21.11.2022 MSK Dissemination of a Corporate News, transmitted by EQS News - a company of EQS Group AG.
  • The EquityStory.RS, LLC Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

PAO Severstal: NOTICE OF MEETING

Retrieved on: 
Wednesday, October 12, 2022
Direct Payments, Information, Severstal, DTC, Securitization, KYC, Person, Russia, Potential, Proposal, Mechanics, Extraordinary resolution, Schedule 5, Loan, Restatement of the Law of Agency, Third, Euroclear, Registrar, Company, Trustee, Negotiation, Trust deed, Acquisition, Protected trust deed, Program, Agency agreement, Amendment, Proxy, Tf–idf, Condition, Trust, Failure, PAO, Competence, Ownership, Principal, Meeting, Security (finance), Property management, Cryptocurrency, Note, Default, Issuer

In accordance with paragraph 7 (Extraordinary Resolution) of Schedule 5 (Provisions for Meetings of Noteholders) of the Trust Deed and Condition 10.1 (Meetings of Noteholders), the Extraordinary Resolution (as defined in the Amended and Restated Principal Trust Deed dated 15 March 2013, as supplemented by the Supplemental Trust Deed dated 16 September 2019 (the "Trust Deed")) shall be passed at a meeting duly convened and held in accordance with the Trust Deed by the affirmative vote of holders of Notes present in person or represented by proxy or representative owning in the aggregate not less than two-thirds in principal amount of the Notes owned by the Noteholders who are so present or represented at the Meeting or such adjourned Meeting.

Key Points: 
  • In accordance with paragraph 7 (Extraordinary Resolution) of Schedule 5 (Provisions for Meetings of Noteholders) of the Trust Deed and Condition 10.1 (Meetings of Noteholders), the Extraordinary Resolution (as defined in the Amended and Restated Principal Trust Deed dated 15 March 2013, as supplemented by the Supplemental Trust Deed dated 16 September 2019 (the "Trust Deed")) shall be passed at a meeting duly convened and held in accordance with the Trust Deed by the affirmative vote of holders of Notes present in person or represented by proxy or representative owning in the aggregate not less than two-thirds in principal amount of the Notes owned by the Noteholders who are so present or represented at the Meeting or such adjourned Meeting.
  • PAO "Severstal" (the "Company") hereby requests that the holders of U.S.$800,000,000 3.15 per cent.
  • Terms not otherwise defined in this Extraordinary Resolution shall have the meaning ascribed thereto in the Consent Solicitation Memorandum dated 12 October 2022.
  • This Extraordinary Resolution and any non-contractual obligations arising out of or in connection with it are governed by, and shall be construed in accordance with, English law.

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Retrieved on: 
Thursday, August 25, 2022
MSD, AstraZeneca, BRCA2, Olaparib, Precision medicine, U.S. Securities and Exchange Commission, Myriad Genetics, GLOBE, Classification, Olympia, Tf–idf, Risk, Patient, BRCA1, Genetics, Death, Genetic testing, SALT, DNA, Cancer, Biomarker, Partnership, MHLW, NASDAQ, Breast International Group, Association for Molecular Pathology v. Myriad Genetics, Inc., New Frontiers Science Park, Ministry of Health, Labour and Welfare, Prequel, Myriad, Private Securities Litigation Reform Act, BRCA, Breast cancer, HIV disease progression rates, MYGN, Nominal interest rate, Sumathi Best Television Current Reporting Award, Fast Company, HER2, Medical imaging, Pharmaceutical industry, Health

This most recent coverage expansion confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.

Key Points: 
  • This most recent coverage expansion confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.
  • BRACAnalysis Diagnostic System is designed to detect and interpret germline BRCA1 and BRCA2 variants.
  • The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2-negative high-risk early breast cancer.
  • BRACAnalysis is a diagnostic system that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.

DGAP-News: Aggregate Holdings SA: Notice of results of put option and intended exercise of clean-up call option

Retrieved on: 
Friday, April 29, 2022
ACT, Trust deed, Intention, Trustee, Commission, MAR, OR, Sale, ARE, AS, ISIN, EUROPEAN UNION, FINANCIAL, EUR, THE, Bond (finance), Redemption, Call, Documentation, Put, Person, Failure, VIC, Condition, Trust, IPO, BNY Corporate Trustees Services Ltd v Eurosail-UK 2007-3BL plc, Tf–idf, OF, UNITED KINGDOM, IT, TIMELY, United Kingdom, Exercise, IF, Agent, ALL, Security (finance), Lease, Issuer, EU, Bond

THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE BONDS.

Key Points: 
  • THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE BONDS.
  • Capitalised terms used but not otherwise defined in this notice shall have the meanings ascribed to them in the Trust Deed.
  • The period for the Bondholders to exercise the Put Right by delivering an Optional Put Exercise Notice expired on 28 April 2022.
  • This notice does not constitute an Optional Redemption Notice for the purposes of the Trust Deed or the Conditions.

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

Retrieved on: 
Saturday, March 12, 2022
Biotechnology, General Health, Pharmaceutical, Health, MSD, Cancer, BRCA, Merck, AstraZeneca, Merck & Co., Tf–idf, Nominal interest rate, Death, Patient, Risk, Pharmaceutical industry, Medical imaging

Compared to placebo, LYNPARZA as adjuvant treatment offers these patients the potential to live longer without their cancer recurring.

Key Points: 
  • Compared to placebo, LYNPARZA as adjuvant treatment offers these patients the potential to live longer without their cancer recurring.
  • LYNPARZA is now indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
  • The PARP inhibitor, LYNPARZA (olaparib), is an approved targeted treatment option for early and metastatic breast cancer patients with an inherited BRCA mutation.
  • Olaparib as Adjuvant Treatment in Patients with Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA).

DeepTarget Celebrates Another Successful Year of New Customers, Partnerships, Alliances, Industry Recognitions and Technology Development in 2021

Retrieved on: 
Thursday, January 13, 2022
Software, Banking, Mobile, Wireless, Internet, Social Media, Professional Services, Data Management, Technology, Other Communications, Marketing, Communications, Finance, Technology, Credit union, Sky One, Publication, NEW, Sun Belt, ATM, Adoption, Fis, Growth, DXP, CEO, Digital, Solution, Automation, API, Digital Impact Awards Africa, Intelligence, Industry, Data mining, Artificial intelligence, AI, Tf–idf, Contract, Michigan Schools and Government Credit Union, Patent, 3D, BI, Alog Datacenters, MDT, DIGITAL, Bank, Marketing

INNOVATION & INTEGRATIONS DXP, featuring innovations such as artificial intelligence, 3D StoryTeller , significant automation, and high scalability, was awarded a patent in October.

Key Points: 
  • INNOVATION & INTEGRATIONS DXP, featuring innovations such as artificial intelligence, 3D StoryTeller , significant automation, and high scalability, was awarded a patent in October.
  • In 2021, new DeepTarget integrations with leading digital banking providers to enable customer-petitioned integrations included Q2 eBanking , Q2 Smart and Jack Henrys Banno digital banking platform.
  • INDUSTRY RECOGNITIONS Finally, DeepTarget was rewarded by the industry.
  • As exciting as 2021 was, our expectation of accelerated adoption of DeepTarget this year has never been higher.

Teekay Corporation Announces Cash Tender Offer for 5.0% Convertible Senior Notes Due 2023

Retrieved on: 
Monday, January 10, 2022
SEC, Risk, Acquisition, Personal Information Agent, Schedule, Tender, Ownership, Transaction, Information, U.S. Securities and Exchange Commission, Settlement date, NYSE, Company, Schedule TO, Tf–idf, Mini-tender offer, LNG, COVID-19, Tender offer, Security (finance), Teekay, Note

The closing of the Teekay LNG Merger is a condition to the closing of the Tender Offer.

Key Points: 
  • The closing of the Teekay LNG Merger is a condition to the closing of the Tender Offer.
  • As described in the Offer to Purchase, tendered Notes may be validly withdrawn from the Tender Offer at or prior to the Expiration Time.
  • The Tender Offer is being made pursuant to the terms and conditions contained in the Offer to Purchase.
  • Holders must make their own decision as to whether to tender their Notes and, if so, the principal amount of Notes to tender.

LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

Retrieved on: 
Tuesday, November 30, 2021
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Patient, Safety, Cancer, Merck, Death, Shanda, Nominal interest rate, Prescription Drug User Fee Act, Recurrence, Priority review, AstraZeneca, Breast cancer, New Drug Application, Risk, BRCA, Olaparib, FDA, Food and Drug Administration Amendments Act of 2007, Merck & Co., Food, Tf–idf, Pharmaceutical industry

The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials.

Key Points: 
  • The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials.
  • LYNPARZA is a targeted treatment option for metastatic breast cancer patients with an inherited BRCA mutation.
  • AstraZeneca with Merck continue to research LYNPARZA in early and metastatic breast cancer patients with a BRCA mutation.
  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).